Arcturus Therapeutics (NASDAQ:ARCT) Rating Reiterated by HC Wainwright

HC Wainwright reissued their buy rating on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a research note released on Tuesday, Benzinga reports. They currently have a $60.00 target price on the biotechnology company’s stock.

Several other research firms have also recently issued reports on ARCT. Canaccord Genuity Group cut their price target on shares of Arcturus Therapeutics from $87.00 to $86.00 and set a buy rating for the company in a report on Friday, May 10th. William Blair reiterated an outperform rating on shares of Arcturus Therapeutics in a research report on Thursday, May 23rd. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and an average price target of $64.86.

Arcturus Therapeutics Trading Up 2.1 %

Arcturus Therapeutics stock opened at $21.93 on Tuesday. The stock has a market capitalization of $590.57 million, a price-to-earnings ratio of -5.61 and a beta of 2.64. The stock has a 50 day moving average of $29.81 and a two-hundred day moving average of $32.42. Arcturus Therapeutics has a twelve month low of $17.52 and a twelve month high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($1.00) earnings per share for the quarter, topping the consensus estimate of ($1.17) by $0.17. The firm had revenue of $38.01 million during the quarter, compared to the consensus estimate of $22.12 million. Arcturus Therapeutics had a negative return on equity of 37.61% and a negative net margin of 81.59%. Equities analysts predict that Arcturus Therapeutics will post -4.39 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Pad Chivukula sold 26,000 shares of Arcturus Therapeutics stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $40.01, for a total transaction of $1,040,260.00. Following the completion of the sale, the chief operating officer now directly owns 447,448 shares in the company, valued at approximately $17,902,394.48. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 13.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ARCT. Russell Investments Group Ltd. acquired a new position in Arcturus Therapeutics during the first quarter worth about $40,000. AJOVista LLC acquired a new position in shares of Arcturus Therapeutics during the 4th quarter worth approximately $65,000. Quest Partners LLC purchased a new stake in Arcturus Therapeutics in the 4th quarter valued at approximately $67,000. Public Employees Retirement System of Ohio purchased a new stake in Arcturus Therapeutics in the 4th quarter valued at approximately $89,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Arcturus Therapeutics by 352.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,089 shares of the biotechnology company’s stock valued at $97,000 after buying an additional 2,406 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.